OTCPK:RSLB.F

Stock Analysis Report

Executive Summary

RaySearch Laboratories AB (publ) operates as a medical technology company that develops software solutions for cancer treatment in North America, Asia, Europe, and internationally.

Snowflake

Fundamentals

Excellent balance sheet with reasonable growth potential.

Risks

  • RaySearch Laboratories has significant price volatility in the past 3 months.
  • RaySearch Laboratories is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has RaySearch Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

RSLB.F

2.5%

US Healthcare Services

-0.6%

US Market


1 Year Return

28.7%

RSLB.F

10.3%

US Healthcare Services

0.6%

US Market

RSLB.F outperformed the Healthcare Services industry which returned 8.7% over the past year.

RSLB.F outperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

RSLB.FIndustryMarket
7 Day0%2.5%-0.6%
30 Day4.3%-2.9%2.2%
90 Dayn/a-4.1%1.1%
1 Year28.7%28.7%10.4%10.3%2.9%0.6%
3 Year-1.3%-1.3%51.9%51.6%44.6%35.2%
5 Year225.0%225.0%52.0%51.1%61.9%44.2%

Price Volatility Vs. Market

How volatile is RaySearch Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is RaySearch Laboratories undervalued based on future cash flows and its price relative to the stock market?

65.89x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

RaySearch Laboratories's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

RaySearch Laboratories's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

RaySearch Laboratories is overvalued based on earnings compared to the US Healthcare Services industry average.

RaySearch Laboratories is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

RaySearch Laboratories is poor value based on expected growth next year.


Price Based on Value of Assets

RaySearch Laboratories is overvalued based on assets compared to the US Healthcare Services industry average.


Next Steps

Future Growth

How is RaySearch Laboratories expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

33.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

RaySearch Laboratories's revenue is expected to grow by 17.3% yearly, however this is not considered high growth (20% yearly).

RaySearch Laboratories's earnings are expected to grow significantly at over 20% yearly.

RaySearch Laboratories's revenue growth is expected to exceed the United States of America market average.

RaySearch Laboratories's earnings growth is expected to exceed the United States of America market average.

RaySearch Laboratories's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

RaySearch Laboratories is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has RaySearch Laboratories performed over the past 5 years?

15.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

RaySearch Laboratories's year on year earnings growth rate has been positive over the past 5 years.

RaySearch Laboratories's 1-year earnings growth is negative, it can't be compared to the 5-year average.

RaySearch Laboratories's 1-year earnings growth is negative, it can't be compared to the US Healthcare Services industry average.


Return on Equity

RaySearch Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

RaySearch Laboratories used its assets more efficiently than the US Healthcare Services industry average last year based on Return on Assets.


Return on Capital Employed

RaySearch Laboratories's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is RaySearch Laboratories's financial position?


Financial Position Analysis

RaySearch Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

RaySearch Laboratories's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

RaySearch Laboratories's level of debt (1.8%) compared to net worth is satisfactory (less than 40%).

Unable to establish if RaySearch Laboratories's debt level has increased without past 5-year debt data.

Debt is well covered by operating cash flow (2394.9%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 20.2x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 44.8x debt.


Next Steps

Dividend

What is RaySearch Laboratories's current dividend yield, its reliability and sustainability?

0.39%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Unable to evaluate RaySearch Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate RaySearch Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as RaySearch Laboratories has not reported any payouts.

Unable to verify if RaySearch Laboratories's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as RaySearch Laboratories has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of RaySearch Laboratories's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of RaySearch Laboratories's salary, the management and board of directors tenure and is there insider trading?

4.0yrs

Average management tenure


CEO

Johan Löf (50yo)

19.7yrs

Tenure

kr9,214,000

Compensation

Dr. Johan Löf has been the Chief Executive Officer and President of Raysearch Laboratories AB (Publ) since 2000. Dr. Löf serves as the Chief Executive Officer of RaySearch Medical AB. Dr. Löf has been a Di ...


CEO Compensation Analysis

Johan's remuneration is lower than average for companies of similar size in United States of America.

Johan's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

4.0yrs

Average Tenure

46yo

Average Age

The tenure for the RaySearch Laboratories management team is about average.


Board Age and Tenure

15.3yrs

Average Tenure

58yo

Average Age

The average tenure for the RaySearch Laboratories board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

RaySearch Laboratories individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Sellkr121,94603 Sep 19
Henrik Friberger
EntityIndividual
Shares7,299
Max Pricekr16.76
Sellkr3,549,50330 Aug 19
Johan Löf
EntityIndividual
Role
Chief Executive Officer
Founder
Shares200,000
Max Pricekr18.96
Sellkr96,26929 Aug 19
Carl Bergendal
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max Pricekr19.25
Buykr58,81521 Feb 19
Johan Löf
EntityIndividual
Role
Chief Executive Officer
Founder
Shares5,370
Max Pricekr10.96

Ownership Breakdown


Management Team

  • Johan Löf (50yo)

    Founder

    • Tenure: 19.7yrs
    • Compensation: kr9.21m
  • Petra Jansson (46yo)

    General Counsel

    • Tenure: 2.2yrs
  • Marc Mlyn

    President of Raysearch Americas Inc

    • Tenure: 0yrs
  • Björn Hårdemark (42yo)

    Deputy Chief Executive Officer

    • Tenure: 4yrs
  • Peter Thysell (49yo)

    Chief Financial Officer

    • Tenure: 4.2yrs
  • Peter Kemlin (45yo)

    Director of Sales & Marketing

    • Tenure: 0yrs
  • Kjell Eriksson (46yo)

    Chief Science Officer

    • Tenure: 4yrs

Board Members

  • Hans Wigzell (81yo)

    Director

    • Tenure: 15.3yrs
    • Compensation: kr221.00k
  • Johan Löf (50yo)

    Founder

    • Tenure: 19.7yrs
    • Compensation: kr9.21m
  • Carl Bergendal (74yo)

    Director

    • Tenure: 19.7yrs
    • Compensation: kr480.00k
  • Lars Wollung (58yo)

    Chairman of the Board

    • Tenure: 0.3yrs
  • Radhe Mohan

    Member of Scientific Advisory Board

    • Tenure: 16.7yrs
  • Anders Forsgren

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Anders Brahme (75yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • David Jaffray

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Johanna Öberg (44yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: kr152.00k
  • Britta Wallgren (56yo)

    Director

    • Tenure: 1.3yrs

Company Information

RaySearch Laboratories AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: RaySearch Laboratories AB (publ)
  • Ticker: RSLB.F
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: kr5.629b
  • Listing Market Cap: kr579.050m
  • Shares outstanding: 34.28m
  • Website: https://www.raysearchlabs.com

Number of Employees


Location

  • RaySearch Laboratories AB (publ)
  • Sveavägen 44
  • Stockholm
  • Stockholm County
  • 111 34
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RAY BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKJun 2003
0GRZLSE (London Stock Exchange)YesClass B SharesGBSEKJun 2003
RSLB.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDJun 2003
27RDB (Deutsche Boerse AG)YesClass B SharesDEEURJun 2003
RAYBSBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBSEKJun 2003

Biography

RaySearch Laboratories AB (publ) operates as a medical technology company that develops software solutions for cancer treatment in North America, Asia, Europe, and internationally. It develops and markets  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:29
End of Day Share Price2019/08/27 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.